Polypill with or without Aspirin in Persons without Cardiovascular Disease

Area of Science:

• Cardiology
• Preventive Medicine
• Pharmacology

Background:

• Cardiovascular disease (CVD) remains a leading cause of mortality worldwide.
• Preventive strategies often involve lifestyle modifications and multiple medications.
• A polypill, combining statins, antihypertensives, and aspirin, is a potential approach to simplify CVD prevention.

Purpose of the Study:

• To evaluate the efficacy and safety of a polypill, aspirin, and their combination in reducing cardiovascular events.
• To assess the impact of these interventions in individuals without pre-existing cardiovascular disease but with elevated cardiovascular risk.

Main Methods:

• A 2x2x2 factorial randomized controlled trial involving 5713 participants with elevated cardiovascular risk.
• Participants received a polypill (simvastatin, atenolol, hydrochlorothiazide, ramipril) or placebo, aspirin or placebo, and vitamin D or placebo.
• Primary outcomes included cardiovascular death, myocardial infarction, stroke, and revascularization, with a mean follow-up of 4.6 years.

Main Results:

• The polypill lowered LDL cholesterol by ~19 mg/dL and systolic blood pressure by ~5.8 mm Hg.
• The polypill alone showed a trend towards reducing primary outcomes (HR 0.79, CI 0.63-1.00).
• Combined polypill and aspirin treatment significantly reduced the primary outcome (HR 0.69, CI 0.50-0.97) compared to double placebo.

Conclusions:

• Combined therapy with a polypill and aspirin effectively reduces the incidence of cardiovascular events in intermediate-risk individuals.
• This combination therapy represents a viable strategy for primary prevention of cardiovascular disease.
• While effective, increased incidence of hypotension and dizziness were noted with polypill use.